Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 4/20 | 0.48 |
| ▸ | ADH1C | P00326 | 3/20 | 0.48 |
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503180 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BFAAHPHGDH | |
| SCHEMBL14397102 | 1.00 | ADH1A (0.48) | ADH1AADH1CADH1BFAAHPHGDH | |
| SCHEMBL104779 | 0.97 | ADH1A (0.44) | ADH1AADH1CADH1BFAAHPHGDH | |
| SCHEMBL10093885 | 0.94 | — | — | |
| SCHEMBL18458215 | 0.85 | ADH1B (0.32) | ADH1AADH1CADH1B | |
| SCHEMBL13397343 | 0.85 | — | — | |
| SCHEMBL23178016 | 0.84 | ADH1C (0.35) | ADH1AADH1CADH1B | |
| SCHEMBL29346796 | 0.82 | ADH1C (0.35) | ADH1AADH1CADH1B | |
| SCHEMBL27089783 | 0.80 | ADH1B (0.33) | ADH1AADH1CADH1B | |
| Methyl Alcohol SCHEMBL28023379 | 0.80 | CCR2 (0.31) | ADH1AADH1CADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023205475-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| CN-1290926-C | Lactic acid polymer composition and molded object thereof | NEW JAPAN CHEM CO LTD (JP) | 2006-12-20 | — | — | CN | disclosed |
| CN-1585802-A | Lactic acid polymer composition and molded object thereof | NEW JAPAN CHEM CO LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| EP-0776933-B1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEM CO LTD (JP) | 1999-08-04 | — | — | EP | disclosed |
| US-4379862-A | Process for the preparation of polyurethane resins using low molecular weight polyhydroxyl compounds prepared by the condensation of formaldehyde | BAYER AKTIENGESELLSCHAFT (DE) | 1983-04-12 | — | — | US | disclosed |
| US-4301310-A | USING SYNTHESIS GAS DIRECTLY AS THE SOURCE OF FORMALDEHYDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-17 | — | — | US | disclosed |
| EP-0001210-B1 | MIXTURES CAPABLE OF REACTING WITH ISOCYANATES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN A PROCESS FOR THE PRODUCTION OF POLYURETHANE-PLASTICS | BAYER AG (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4219508-A | FROM CONDENSATION OF UNPURIFIED FORMALDEHYDE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-26 | — | — | US | disclosed |
| EP-0001210-A1 | Mixtures capable of reacting with isocyanates, process for their preparation and their use in a process for the production of polyurethane-plastics | BAYER AG (DE) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | ADH1A 3768/4885ADH1C 2836/4885ADH1B 3176/4885 |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | PTPN5, PTPN2, PTPN1 | ADH1A 3661/4885ADH1C 3076/4885ADH1B 3540/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ADH1A 2036/4885ADH1C 2326/4885ADH1B 2032/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | ADH1A 1620/4885ADH1C 659/4885ADH1B 396/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | ADH1A 2036/4885ADH1C 2326/4885ADH1B 2032/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ADH1A 4306/4885ADH1C 4321/4885ADH1B 3094/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | ADH1A 4855/4885ADH1C 4854/4885ADH1B 3951/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | ADH1A 3124/4885ADH1C 2203/4885ADH1B 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.